- Exchange: Toronto
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
BELLUS Health Inc
+ Add to WatchlistBLU:CN
0.3200 CAD 0.0200 6.67%As of 14:30:27 ET on 05/17/2013.
Snapshot for BELLUS Health Inc (BLU)
| Open: | 0.3100 | Day's Range: | 0.3100 - 0.3200 | Volume: | 4,003 |
|---|---|---|---|---|---|
| Previous Close: | 0.3000 | 52wk Range: | 0.2400 - 1.2000 | 1-Yr Rtn: | -69.52% |
Key Statistics for BLU
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(-) | - |
| Relative P/E vs. SPTSX | - |
| Earnings Per Share (ttm) | -0.7500 |
| Est. EPS | - |
| Est. PEG Ratio | - |
| Market Cap (M CAD) | 15.18 |
| Shares Outstanding (M) | 47.43 |
| 30 Day Average Volume | 253,984 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 3.5305 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for BLU
Company Profile & Key Executives for BLU
BELLUS Health Inc. develops and commercializes therapeutics for neurological disorders. The Company has products in clinical trials for AA amyloidosis, the treatment of Alzheimer's Disease, and for the prevention of hemorrhagic stroke caused by amyloid angiopathy.
| Roberto BelliniPresident/CEO | Denis GarceauSenior VP:Drug Development |
| Francois DesjardinsVP:Finance | Tony MatzouranisVP:Business Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
BLU News
-
Industry News
No stories found
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page